PubMed HealthSearch

PubMed · 40996584

Image-guided biopsy of breast lesions-when to use what biopsy technique.

Abstract

In recent years, minimally invasive diagnostic options for breast lesions have expanded, but consensus on optimal biopsy techniques and imaging combinations remains lacking. This study, driven by an adapted RAND-UCLA Appropriateness Method and insights from eight experts in breast biopsy from across the world, aims to create consensus for selecting biopsy techniques. Highlighted findings suggest Vacuum-Assisted Biopsy (VAB) for lesions visible exclusively at mammography/tomosynthesis (with or without contrast enhancement) or MRI. Core-needle biopsy (CNB) takes precedence for masses over 5&#x2009;mm visible under US. The selection of other biopsy techniques during US-guided procedures depends on lesion type, size, and sampling indication. VAB is preferred for smaller masses (<&#x2009;5&#x2009;mm), complex cystic and solid lesions with small solid parts, small intraductal masses, architectural distortions, and calcifications visible on US. In re-biopsy scenarios for inconclusive findings or high-risk lesions, the panel suggests two VAB extensions: Extended Vacuum-Assisted Biopsy (EVAB) for unambiguous lesion classification and Vacuum-Assisted Excision (VAE) for complete lesion removal. Furthermore, the panel provides detailed input on how to handle specific cases, such as re-biopsy for lobular neoplasia, flat epithelial atypia and atypical ductal hyperplasia. Surgical excision is advised for DCIS and benign or borderline phyllodes tumors found through initial CNB or VAB. In conclusion, an international expert group formulated recommendations on diagnostic breast biopsies under image guidance, aiming to ensure accurate diagnosis worldwide by providing practical advice on needle selection and biopsy approach. KEY POINTS: Evidence-based literature on the preferred biopsy technique and imaging combination for the diagnosis of breast lesions is sparse, and a general consensus is not available. The selection of biopsy technique for different image-guided procedures depends on lesion type, size, and sampling indication. This international expert panel consensus statement addresses standard approaches for varying biopsy indications.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Wendelien B G Sanderink, Julia Camps-Herrero, Alexandra Athanasiou, Henrique L Couto, Kirti Mehta, Popat Palak Bhavesh Thakkar, Pooja Jagmohan, Sara E V&#xe1;zquez-Manjarrez, Seigo Nakamura, Jelle Wesseling, Ritse M Mann. 2025-09-25. Image-guided biopsy of breast lesions-when to use what biopsy technique.. https://doi.org/10.1186/s13244-025-02084-5

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Transcriptomic signatures of mind-body transformations therapy in breast cancer: Downregulation of the interferon signaling pathway.

BACKGROUND: Growing evidence has shown that Mind-Body Transformations-Therapies (MBT-T) are able to modulate chronic inflammation, a well-known driver of cancer progression and drug resistance. In our previous work, we showed that a specific MBT-T protocol was able to reduce the release of various pro-inflammatory cytokines and chemokines in the sera of patients with breast cancer that completed adjuvant chemotherapy. Despite these clinical observations, the underlying molecular pathways through which this therapy exerts its effects remain unclear. This study aims to address this gap by characterizing genome-wide transcriptional profiles in patients undergoing a novel MBT-T protocol. METHODS: In this proof-of-concept study, patients with breast cancer were randomized into two groups: Group 1 (CTL), receiving standard follow-up care, and Group 2 (MBT-T), receiving standard follow-up plus biweekly MBT-T for 4 months. Blood samples were collected at different timepoints during the treatment. After RNA extraction from whole blood, gene expression was analyzed on twenty-one patients (CTL, n&#x202f;=&#x202f;7; MBT-T, n&#x202f;=&#x202f;14) using the nCounter&#xae; Human Inflammation Panel (249 genes). RESULTS: Patients undergoing MBT-T showed a significant global downregulation of inflammatory gene expression compared to the control group. The analysis revealed that the Interferon (IFN) signaling pathway was the most significantly suppressed, by downregulation of key genes such as IFIT1, IFIT3, IFI44, MX1 and OASL in the MBT-T group. CONCLUSIONS: MBT-T acts as a biological modulator capable of downregulating key inflammatory pathways at the transcriptional level. These findings provide a genomic basis for the clinical benefits of mind-body interventions in oncology.

Breast cancer

Unveiling novel transcriptomic prognostic biomarkers for specific breast cancer subtypes and treatment regimens.

BACKGROUND: Breast cancer (BRCA) is the most common cancer in women worldwide, yet current gene expression panels offer limited insight into treatment responses across different subtypes and therapies. This study aimed to identify reliable biomarkers for predicting treatment outcomes in specific BRCA subtypes and treatment regimens. METHODS: This study analyzed transcriptomic data from The Cancer Genome Atlas to identify differentially expressed genes (DEGs) in patient groups treated with different combinations of hormone therapy (H), chemotherapy (C), radiotherapy (R), and targeted therapy (T). Non-negative matrix factorization clustering was performed to stratify patients into clusters representing different BRCA subtypes. Functional enrichment analysis was performed, and survival assessments were conducted using the METABRIC dataset. RESULTS: A total of 1,148 DEGs were identified across treatment regimens, with 75 common DEGs shared across multiple regimens. Among these, 12 candidate biomarkers were associated with luminal subtypes treated with H, including LRP1B, of which high expression predicted cancer recurrence. In triple-negative breast cancer (TNBC) treated with C, 76 candidate biomarkers were identified, including TTYH1 for recurrence and ANXA8L1 and MPZ for non-recurrence. Functional analyses identified intermediate filament organization and keratinization as pathways associated with specific candidate biomarkers of TNBC following C. Survival analysis using METABRIC strengthened the prognostic ability of LRP1B and TTYH1 to predict worse survival and ANXA8L1 and MPZ to predict prolonged survival, with four additional prognostic biomarkers. CONCLUSION: This study identified gene expression prognostic biomarkers for luminal and TNBC subtypes, thereby supporting personalized therapies. Further experimental validation is required to confirm these findings for clinical application. CLINICAL TRIAL REGISTRY: No.

Breast cancer

Prognostic role of thymidine kinase 1 activity in hormone receptor positive metastatic breast cancer. A systematic review and meta-analysis.

INTRODUCTION: Circulating thymidine kinase 1 activity (TKa) is a potential prognostic biomarker in patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC); however, results are heterogeneous. In this study we aimed to summarize the current evidence on the prognostic role of circulating TKa in women with HR+&#xa0;MBC. METHODS: We conducted a systematic review of PubMed, Embase, and Cochrane CENTRAL databases and abstracts from main international oncology meetings. Phase II-IV clinical trials and prospective observational studies in patients with MBC assessing circulating TK1 levels or TKa and reporting hazard ratios (HRs) for progression-free survival (PFS) and/or overall survival (OS) were included. HRs were pooled using random-effects models (restricted maximum likelihood with Hartung-Knapp adjustment), with heterogeneity quantified by I2 and prediction intervals. The primary study outcome was the association of baseline and on-treatment TKa with PFS and OS. Secondary analyses aimed at exploring the source of heterogeneity. RESULTS: Eighteen studies, reporting data from nearly 3000 women, were included in the systematic review and 15 studies were meta-analyzed. Patients with HR+&#xa0;MBC and high baseline TKa showed a significantly higher risk of progression (PFS: HR 1.90; 95% CI 1.57-2.30; p&#xa0;<&#xa0;0.001) and death (OS: HR 2.48; 95% CI 1.94-3.17; p&#xa0;<&#xa0;0.001) than those with low TKa. TKa at 2 and 4 weeks on-treatment was also prognostic (2 weeks, PFS: HR 2.76; 95% CI 2.34-3.26; p&#xa0;<&#xa0;0.001; 4 weeks, HR 2.26; 95% CI 1.93-2.66; p&#xa0;<&#xa0;0.001). Similar pooled effects were obtained when accounting for different cut-offs, TKa assessment, and sample-type. CONCLUSION: Pre-treatment high TKa is an adverse prognostic factor in women with HR+&#xa0;MBC. High on-treatment TKa is also associated with worse outcome, potentially serving as an early signal of treatment resistance. We provide a comprehensive summary of the currently available evidence on the prognostic value of circulating TKa.

Breast cancer